Skip to main content
. 2021 Nov 15;23(1):47. doi: 10.3892/etm.2021.10969

Figure 4.

Figure 4

AVA4746 decreases the number of human B-ALL cells in the mouse peripheral blood samples whilst increasing the number of ALL cells in the bone marrow. (A) Experimental design of the in vivo leukemic cell mobilization assay. When 0.5% of human CD45/CD19 double-positive LAX7R cells were detected by flow cytometry in the PB of the NSG mice, mice were treated with either PBS (n=7) or 60 mg/kg AVA4746 (n=7). Mononuclear cells were isolated from the PB, BM and SPC 36 h after treatment. Percentages of hCD45+hCD19+cells in the (B) PB, (C) BM and (D) SPC are shown. *P<0.05. PB, peripheral blood, BM, bone marrow; SPC, spleen; NSG, NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ; NS, no significant; B-ALL, B-lineage acute lymphoblastic leukemia.